You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

The New Cardiometabolic Strategy From A to Z: Cardiometabolic Strategy to Treat T2D

  • Authors: Guillermo Umpierrez, MD; Martha Gulati, MD, MS; Shivani Agarwal, MD, MPH; John Buse, MD, PhD; James L. Januzzi Jr, MD, FACC, FESC; Robert Kushner, MD, MS, FACP; Darren K. McGuire, MD, MHSc; Katherine Tuttle, MD
  • CME / ABIM MOC / CE Released: 12/22/2021
  • Valid for credit through: 12/22/2022
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetelogists/endocrinologists, primary care physicians, nephrologists, nurses/nurse practitioners, physician assistants, and other health care professionals involved in the care of patients at risk of CV events, including patients with type 2 diabetes (T2D) and comorbidities.

The goal of this activity is to increase awareness of the relationship between cardiovascular disease, T2D, obesity, and kidney disease, including strategies to treat T2D using a cardiometabolic-centric approach.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Physiology and clinical importance of the interconnection between T2D, CVD, CKD, and/or obesity
    • Impact on health outcomes of AEs/comorbidities commonly seen in patients with T2D, CVD, CKD, and/or obesity
    • Data supporting strategies to benefit CVD, diabetes, and kidney disease in complicated patients
    • Strategies for effective management of AEs/comorbidities in patients with T2D, CVD, CKD, and/or obesity (eg, hyperkalemia, anemia, hypoglycemia)
  • Have greater competence related to
    • Identification of patients needing CV risk reduction and weight loss via use of agents with CV/renal/weight benefits
    • Secondary CV risk reduction in high-risk patients with T2D, atherosclerotic CVD (ASCVD), CKD, and/or heart failure (HF)


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Co-Chairs

  • Guillermo Umpierrez, MD

    Professor of Medicine
    Division of Endocrinology, Metabolism
    Emory University School of Medicine
    Chief
    Diabetes and Endocrinology
    Grady Memorial Hospital
    Atlanta, Georgia

    The opinions expressed are those of Dr Umpierrez and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Umpierrez's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosures

    Disclosure: Guillermo Umpierrez, MD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: AstraZeneca; Dexcom; Novo Nordisk

  • Martha Gulati, MD, MS

    Editor-in-Chief
    CardioSmart for The American College of Cardiology
    Washington, DC
    President-Elect
    American Society for Preventive Cardiology
    Jacksonville, Florida

    Disclosures

    Disclosure: Martha Gulati, MD, MS, has disclosed no relevant financial relationships.

Faculty

  • Shivani Agarwal, MD, MPH

    Assistant Professor
    Albert Einstein College of Medicine
    Director
    Supporting Emerging Adults With Diabetes Program (SEAD)
    Montefiore
    Bronx, New York

    Disclosures

    Disclosure: Shivani Agarwal, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Medtronic, Inc.
    Received grants for clinical research from: Dexcom

  • John Buse, MD, PhD

    Chief, Division of Endocrinology
    Verne S. Caviness Distinguished Professor
    Director, Diabetes Center
    Director, NC Translational and Clinical Sciences Institute
    UNC School of Medicine
    Chapel Hill, North Carolina

    Disclosures

    Disclosure: John Buse, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Anji Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Cirius Therapeutics Inc; Eli Lilly; Fortress Biotech; Glyscend; Janssen; Moderna; Pendulum Therapeutics; Praetego; Zealand Pharma
    Received grants for clinical research from: AstraZeneca; Dexcom; Eli Lilly; Intarcia Therapeutics; Johnson & Johnson; Lexicon; NovaTarg; Novo Nordisk; Sanofi; Theracos; Tolerion; vTv Therapeutics
    Owns stock, stock options, or bonds from: Pendulum Therapeutics; PhaseBio; Praetego
    Other: Contracted consulting fees and travel support for contracted activities are paid to the University of North Carolina by Adocia; AstraZeneca; Eli Lilly; Intarcia Therapeutics; MannKind; Novo Nordisk; Sanofi; Senseonics; vTv Therapeutics

  • James L. Januzzi Jr, MD, FACC, FESC

    Hutter Family Professor of Medicine
    Harvard Medical School
    Physician, Cardiology Division
    Massachusetts General Hospital
    Senior Cardiometabolic Faculty
    Baim Institute for Clinical Research
    Boston, Massachusetts

    Disclosures

    Disclosure: James L. Januzzi Jr, MD, FACC, FESC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbott; Janssen; Novartis; Roche Diagnostics
    Received grants for clinical research from: Abbott; Applied Therapeutics; Innolife; Novartis

  • Robert Kushner, MD, MS, FACP

    Professor of Medicine
    Departments of Medicine and Medical Education
    Northwestern University Feinberg School of Medicine
    Center for Lifestyle Medicine
    Northwestern Medicine
    Chicago, Illinois

    Disclosures

    Disclosure: Robert Kushner, MD, MS, FACP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Novo Nordisk; Pfizer
    Received grants for clinical research from: Epitomee; Novo Nordisk

  • Darren K. McGuire, MD, MHSc

    Distinguished Teaching Professor of Medicine
    University of Texas Southwestern Medical Center
    Parkland Health and Hospital System
    Dallas, Texas

    Disclosures

    Disclosure: Darren K. McGuire, MD, MHSc, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Applied Therapeutics; Bayer; Boehringer Ingelheim; CSL Behring; Lilly USA; Merck & Co.; Metavante; Novo Nordisk; Sanofi Aventis
    Other: Honoraria for trial leadership: AstraZeneca; Boehringer Ingelheim; CSL Behring; Lexicon; Lilly USA; Merck & Co.; Novo Nordisk; Pfizer; Sanofi Aventis

  • Katherine Tuttle, MD

    Executive Director for Research
    Providence Health Care
    Professor of Medicine
    Nephrology Division and Kidney Research Institute
    Institute of Translational Health Sciences
    University of Washington
    Spokane, Washington

    Disclosures

    Disclosure: Katherine Tuttle, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Bayer; Boehringer Ingelheim; Gilead; Goldfinch Bio; Novo Nordisk; Travere
    Received grants for clinical research from: Goldfinch Bio; Travere

Editor

  • Anne G. Le, PharmD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

CME Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

All other faculty, planners and non-faculty contributors involved in the planning, development, editing, and review of the content have no relevant financial relationships with ineligible companies.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds: Roche Diagnostics Inc

 


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

The New Cardiometabolic Strategy From A to Z: Cardiometabolic Strategy to Treat T2D

Authors: Guillermo Umpierrez, MD; Martha Gulati, MD, MS; Shivani Agarwal, MD, MPH; John Buse, MD, PhD; James L. Januzzi Jr, MD, FACC, FESC; Robert Kushner, MD, MS, FACP; Darren K. McGuire, MD, MHSc; Katherine Tuttle, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/22/2021

Valid for credit through: 12/22/2022

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

SGLT2 Inhibitors in Patients with T2D and ASCVD or HF

James L. Januzzi Jr, MD, FACC, FESC

GLP-1 RAs in Patients With T2D and ASCVD

John B. Buse, MD, PhD

Hypoglycemia and CV Events: What Does the Cardiologist Need to Know?

Darren K. McGuire, MD, MHSc

Role of the Kidney in Cardiovascular Disease and Type 2 Diabetes

Katherine R. Tuttle, MD, FASN, FACP, FNKF

Obesity and Its Impact on Cardiometabolic Comorbidities

Robert Kushner, MD, MS, FACP

Women and Minorities: Cardiometabolic Conditions and Management

Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC

Cardiometabolic Management in the Era of COVID-19

Shivani Agarwal, MD, MPH